Schering-Plough Adopts Global Model for Clinical Trials

Schering-Plough Corp. has announced plans to adopt a new global model for its clinical trial operations, designed to maximize its product portfolio through centralized global processes and functional units that are “efficient, compliant and customer-focused.” This model is expected to enhance how the company plans and manages the progression of therapeutic compounds through clinical trials toward commercialization.

Under the Global Clinical Harmonization (GCH) program, all clinical trials will be held to a consistent set of standards regardless of trial type, phase or geography. Global Clinical Operations (GCO) will establish this global set of standards, policies and practices, and build a management system that will oversee clinical trials worldwide.

“When fully implemented, the new model we are adopting is designed to result in a global, standardized approach to how we conduct clinical trials,” said Brent Saunders, senior vice president, Global Compliance and Business Practices, and project executive chair. “This new model, which replaces a previously decentralized approach, should help ensure better planning and prioritization, greater consistency in trial execution and improved cost efficiencies.”